Monitoring of Neurocognitive Function in the Care of Patients with Brain Tumors
Purpose of review
A detailed characterization of the nature of neurocognitive impairment in patients with brain tumors is provided, as well as considerations for clinical practice regarding neuropsychological assessment throughout the disease course.
Neurocognitive impairment is common in patients with brain tumors and may result from the tumor itself, as a consequence of treatment, including surgery, chemotherapy, and radiation, or in association with supportive care medications (e.g., anticonvulsant and pain medications). Serial surveillance of neurocognitive functioning in this population can facilitate medical decision-making and inform recommendations to improve patient daily functioning and quality of life.
Neuropsychological assessment is increasingly recognized as a critical component of the multidisciplinary care of patients with brain tumors and has already had practice-changing effects. Further understanding of genetic risk factors for neurocognitive decline along with the development of novel assessment and intervention strategies may further enhance functioning and general well-being in this patient population.
KeywordsBrain tumor Glioma Neurocognitive function Quality of life
Jeffrey S. Wefel is supported by the National Institute of Nursing Research of the National Institutes of Health under Award Number R01NR014195. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Compliance with Ethical Standards
Conflict of Interest
Kyle R. Noll, Mariana E. Bradshaw, Erica L. Dawson, and Jennie Rexer each declare no potential conflict of interest. Michael W. Parsons reports consulting fees from Agios Inc. and Monteris Inc. outside the submitted work. Jeffrey S. Wefel reports personal fees from Abbvie, Bayer, Blueprint Medicines, Magnolia Tejas, Novocure, and Vanquish Oncology, and reports grants from Angiochem, Juno, Novocure, and Roche outside the submitted work.
Human and Animal Rights and Informed Consent
All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 6.Meyers CA, Wefel JS. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21(19):3557–8. https://doi.org/10.1200/JCO.2003.07.080JCO.2003.07.080.CrossRefGoogle Scholar
- 7.Racine CA, Li J, Molinaro AM, Butowski N, Berger MS. Neurocognitive function in newly diagnosed low-grade glioma patients undergoing surgical resection with awake mapping techniques. Neurosurgery. 2015;77(3):371–9: discussion 9. https://doi.org/10.1227/NEU.0000000000000779.CrossRefPubMedGoogle Scholar
- 12.Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro-Oncology. 2018;20(suppl_4):iv1–iv86. https://doi.org/10.1093/neuonc/noy131.CrossRefPubMedGoogle Scholar
- 14.Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–20. https://doi.org/10.1007/s00401-016-1545-1.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Noll KR, Sullaway C, Ziu M, Weinberg JS, Wefel JS. Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection. Neuro-Oncology. 2014;17(4):580–7. https://doi.org/10.1093/neuonc/nou233.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Wefel JS, Parsons MW, Gondi V, Brown PD. Neurocognitive aspects of brain metastasis. Handb Clin Neurol. 2018;149:155–65. https://doi.org/10.1016/B978-0-12-811,161-1.00012-8.CrossRefPubMedGoogle Scholar
- 22.••Kesler SR, Noll K, Cahill DP, Rao G, Wefel JS. The effect of IDH1 mutation on the structural connectome in malignant astrocytoma. J Neuro-Oncol. 2016. https://doi.org/10.1007/s11060-016-2328-1 The first demonstration of the impact of tumor genetic variation upon network integrity in patients with malignant astrocytoma. Patients with wild-type tumor demonstrated significantly lower network efficiency in medial frontal, posterior parietal, and subcortical regions.CrossRefGoogle Scholar
- 30.Armstrong TS, Wefel JS, Wang M, Gilbert MR, Won M, Bottomley A, et al. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2013;31(32):4076–84. https://doi.org/10.1200/JCO.2013.49.6067.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Prust ML, Jafari-Khouzani K, Kalpathy-Cramer J, Polaskova P, Batchelor TT, Gerstner ER, et al. Standard chemoradiation in combination with VEGF targeted therapy for glioblastoma results in progressive gray and white matter volume loss. Neuro-Oncology. 2018;20(2):289–91. https://doi.org/10.1093/neuonc/nox217.CrossRefPubMedPubMedCentralGoogle Scholar
- 36.• Makale MT, McDonald CR, Hattangadi-Gluth JA, Kesari S. Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumors. Nat Rev Neurol. 2017;13(1):52–64. https://doi.org/10.1038/nrneurol.2016.185 Comprehensively reviews the mechanisms of nerual damage underlying cognitive deterioriation in patients attributable to radiation therapy, including inflammation, injury to neuronal lineages, accessory cells and their progenitors, and loss of supporting structure integrity.CrossRefPubMedGoogle Scholar
- 41.Gehring KSA, Etzel C, Lang F, Wefel J. Prediction of memory outcomes after resection of high-grade glioma (Abstract). Neuro-Oncology. 2011;13:iii73.Google Scholar
- 42.Gehring KSA, Etzel C, Lang F, Wefel J. Prediction of language outcomes after resection of high-grade glioma (Abstract). Neuro-Oncology. 2011;13:iii75.Google Scholar
- 44.•• Kelm A, Sollmann N, Ille S, Meyer B, Ringel F, Krieg SM. Resection of gliomas with and without neuropsychological support during awake craniotomy-effects on surgery and clinical outcome. Front Oncol. 2017;7:176. https://doi.org/10.3389/fonc.2017.00176 Demonstrates the benefit of incorporating neuropsychology services during awake craniotomy—namely that greater extent of resection and reduced surgical time are achieved.CrossRefPubMedPubMedCentralGoogle Scholar
- 47.•• Noll KR, Sullaway CM, Wefel JS. Depressive symptoms and executive function in relation to survival in patients with glioblastoma. J Neuro-Oncol. 2019;142(1):183–91. https://doi.org/10.1007/s11060-018-03081-z Demonstrates the independent and combined impact of executive functioning and depressive symptoms upon surival duration in patients with glioblastoma. Patients with increased depressive ideation or executive dysfunction appear at risk of reduced survival, while those with both exhibit the worst prognosis.CrossRefGoogle Scholar
- 50.Mandonnet E, De Witt Hamer P, Poisson I, Whittle I, Bernat AL, Bresson D, et al. Initial experience using awake surgery for glioma: oncological, functional, and employment outcomes in a consecutive series of 25 cases. Neurosurgery. 2015;76(4):382–9; discussion 9. https://doi.org/10.1227/NEU.0000000000000644.CrossRefPubMedGoogle Scholar
- 67.Postal K, Armstrong K. Feedback That Sticks: The Art of effectively communicating neuropsychological assessment results. New York: Oxford University Press; 2013.Google Scholar
- 70.Gehring K, Patwardhan SY, Collins R, Groves MD, Etzel CJ, Meyers CA, et al. A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor. J Neuro-Oncol. 2011;107(1):165–74. https://doi.org/10.1007/s11060-011-0723-1.CrossRefGoogle Scholar
- 72.Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro-Oncology. 2013;15(10):1429–37. https://doi.org/10.1093/neuonc/not114.CrossRefPubMedPubMedCentralGoogle Scholar
- 73.Boele FW, Douw L, de Groot M, van Thuijl HF, Cleijne W, Heimans JJ, et al. The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. Neuro-Oncology. 2013;15(10):1420–8. https://doi.org/10.1093/neuonc/not102.CrossRefPubMedPubMedCentralGoogle Scholar
- 74.Day J, Zienius K, Gehring K, Grosshans D, Taphoorn M, Grant R, et al. Interventions for preventing and ameliorating cognitive deficits in adults treated with cranial irradiation. Cochrane Database Syst Rev. 2014;(12):Cd011335. https://doi.org/10.1002/14651858.CD011335.pub2.
- 75.• Noll KR, Bradshaw ME, Weinberg JS, Wefel JS. Neurocognitive functioning is associated with functional independence in newly diagnosed patients with temporal lobe glioma. Neurooncol Pract. 2018;5(3):184–93. https://doi.org/10.1093/nop/npx028 Results show that neurocognitive impairment as identified on neuropsychological testing is related to difficulties in various functional capacities, including basic and instrumental daily tasks.CrossRefPubMedGoogle Scholar
- 76.•• Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316(4):401–9. https://doi.org/10.1001/jama.2016.9839Practice-changing research showing differential impact of whole-brain radiation versus radiosurgery upon neurocognitive functioning in patients with brain metastases.CrossRefPubMedPubMedCentralGoogle Scholar
- 77.Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomized controlled trial. Lancet Oncol. 2009;10(11):1037–44. https://doi.org/10.1016/S1470-2045(09)70263-3.CrossRefPubMedGoogle Scholar
- 78.Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(34):3810–6. https://doi.org/10.1200/jco.2014.57.2909.CrossRefGoogle Scholar
- 79.•• Wefel JS, Noll KR, Rao G, Cahill DP. Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection. Neuro-Oncology. 2016;18(12):1656–63. https://doi.org/10.1093/neuonc/now165 First demonstration of the distinct neurocognitive phenotypes associated with variation in the IDH1 gene in patients with malignant glioma. Results indicate that patients with IDH1-wild-type tumors present with more severe impairment due to greater lesion momentum.CrossRefPubMedPubMedCentralGoogle Scholar
- 80.Ahles TA, Saykin AJ, Noll WW, Furstenberg CT, Guerin S, Cole B, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003;12(6):612–9. https://doi.org/10.1002/pon.742.CrossRefPubMedGoogle Scholar
- 82.• Correa DD, Satagopan J, Cheung K, Arora AK, Kryza-Lacombe M, Xu Y, et al. COMT, BDNF, and DTNBP1 polymorphisms and cognitive functions in patients with brain tumors. Neuro-Oncology. 2016;18(10):1425–33. https://doi.org/10.1093/neuonc/now057 Large cohort study of associations between various patient genetic polymorphisms and neurocognition in patients with brain tumors. Various polymorphisms in genes associated with executive and memory functions appear to modulate cognitive outcome in patients with brain tumors.CrossRefPubMedPubMedCentralGoogle Scholar
- 85.Bauer RM, Iverson GL, Cernich AN, Binder LM, Ruff RM, Naugle RI. Computerized neuropsychological assessment devices: joint position paper of the American Academy of Clinical Neuropsychology and the National Academy of Neuropsychology. Clin Neuropsychol. 2012;26(2):177–96. https://doi.org/10.1080/13854046.2012.663001.CrossRefPubMedGoogle Scholar
- 88.Cerhan JH, Caine C, Anderson SK, Johnson DR, Lachance DH, Yan E, et al. Preliminary exploration of a computerized cognitive battery and comparison with traditional testing in patients with high-grade glioma. Neuro-Oncol Pract. 2019;6(1):71–7. https://doi.org/10.1093/nop/npy013.CrossRefGoogle Scholar
- 90.• Feenstra HE, Vermeulen IE, Murre JM, Schagen SB. Online self-administered cognitive testing using the Amsterdam Cognition Scan: establishing psychometric properties and normative data. J Med Internet Res. 2018;20(5):e192. https://doi.org/10.2196/jmir.9298Description of an emerging online computerized cognitive testing platform with potential for use in cancer populations. Initial psychometric properties are described.CrossRefPubMedPubMedCentralGoogle Scholar
- 91.Feenstra HEM, Murre JMJ, Vermeulen IE, Kieffer JM, Schagen SB. Reliability and validity of a self-administered tool for online neuropsychological testing: The Amsterdam Cognition Scan. J Clin Exp Neuropsychol. 2018;40(3):253–73. https://doi.org/10.1080/13803395.2017.1339017.CrossRefPubMedGoogle Scholar
- 94.• Blakeley JO, Coons SJ, Corboy JR, Kline Leidy N, Mendoza TR, Wefel JS. Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations. Neuro-Oncology. 2016;18(Suppl 2):ii13–20. https://doi.org/10.1093/neuonc/nov291 This review critically describes various clinical outcome assessment measures used in malignant glioma clinical trials through results of a survey conducted by the National Brain Tumor Society. Areas of need for future development are highlighted.CrossRefPubMedPubMedCentralGoogle Scholar
- 96.van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, et al. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12(6):583–93. https://doi.org/10.1016/S1470-2045(11)70057-2.CrossRefPubMedGoogle Scholar
- 97.Lin NU, Wefel JS, Lee EQ, Schiff D, van den Bent MJ, Soffietti R, et al. Challenges relating to solid tumor brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol. 2013;14(10):e407–16. https://doi.org/10.1016/S1470-2045(13)70308-5.CrossRefPubMedGoogle Scholar
- 98.NCCN. NCCN Clinical Practice Guidelines in Oncology - Survivorship. 2019. https://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf. Accessed 4/8/2019 2019.